MX2016013600A - Método para tratar adenocarcinoma de pulmón. - Google Patents

Método para tratar adenocarcinoma de pulmón.

Info

Publication number
MX2016013600A
MX2016013600A MX2016013600A MX2016013600A MX2016013600A MX 2016013600 A MX2016013600 A MX 2016013600A MX 2016013600 A MX2016013600 A MX 2016013600A MX 2016013600 A MX2016013600 A MX 2016013600A MX 2016013600 A MX2016013600 A MX 2016013600A
Authority
MX
Mexico
Prior art keywords
lung adenocarcinoma
ros1
patient
treating lung
cancer
Prior art date
Application number
MX2016013600A
Other languages
English (en)
Inventor
T Aftab Dana
Yu Peiwen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055132&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2016013600A publication Critical patent/MX2016013600A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La presente invención se refiere al tratamiento de cáncer en un paciente, particularmente un paciente con adenocarcinoma de pulmón, y más particularmente un paciente con cáncer de pulmón no microcítico positivo para la fusión SLC34A2-ROS1, CD74-ROS1, o FIG-ROS1, con un inhibidor de MET, VEGFR, y ROS1 que es un compuesto de Fórmula I: Véase formula. O una sal farmacéuticamente aceptable de este.
MX2016013600A 2014-04-25 2015-04-27 Método para tratar adenocarcinoma de pulmón. MX2016013600A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984599P 2014-04-25 2014-04-25
PCT/US2015/027800 WO2015164869A1 (en) 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma

Publications (1)

Publication Number Publication Date
MX2016013600A true MX2016013600A (es) 2017-04-27

Family

ID=53055132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013600A MX2016013600A (es) 2014-04-25 2015-04-27 Método para tratar adenocarcinoma de pulmón.

Country Status (21)

Country Link
US (1) US20170042880A1 (es)
EP (2) EP3906921A1 (es)
JP (2) JP6696908B2 (es)
KR (1) KR102474701B1 (es)
CN (1) CN106488768A (es)
AR (1) AR100191A1 (es)
AU (1) AU2015249232B2 (es)
BR (1) BR112016024672A2 (es)
CA (1) CA2946416C (es)
DK (1) DK3134084T3 (es)
EA (1) EA035223B1 (es)
ES (1) ES2874875T3 (es)
HU (1) HUE054557T2 (es)
IL (1) IL248408B (es)
MX (1) MX2016013600A (es)
PL (1) PL3134084T3 (es)
PT (1) PT3134084T (es)
SG (1) SG11201608657QA (es)
TW (1) TWI724988B (es)
UA (1) UA121655C2 (es)
WO (1) WO2015164869A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029506B1 (ru) 2011-05-02 2018-04-30 Экселиксис, Инк. Способ лечения рака и раковой боли в костях
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
ES2929888T3 (es) 2014-07-31 2022-12-02 Exelixis Inc Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos
CA2957466C (en) 2014-08-05 2023-10-17 Exelixis, Inc. Drug combinations to treat multiple myeloma
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
CN107353246A (zh) * 2016-12-27 2017-11-17 辅仁药业集团熙德隆肿瘤药品有限公司 一种制备抗肿瘤药物卡博替尼的方法
JP2020521440A (ja) * 2017-05-31 2020-07-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｌｋ、ｒｅｔ、およびｒｏｓ融合の多重ｐｃｒ検出
CA3065560A1 (en) 2017-06-09 2018-12-13 Exelixis, Inc. Liquid dosage forms to treat cancer
CN107541550A (zh) * 2017-08-21 2018-01-05 上海派森诺生物科技股份有限公司 人ros1融合基因检测方法
JP7279026B2 (ja) * 2017-09-20 2023-05-22 メルサナ セラピューティクス インコーポレイテッド Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
MA51679A (fr) 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement de troubles dépendant de la kinase
CA3088200A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
DE102020005002A1 (de) * 2020-08-17 2022-02-17 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Mittel zur Therapie von Tumorerkrankungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
KR20200137052A (ko) * 2009-01-16 2020-12-08 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
US9364477B2 (en) 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
EP2892532B1 (en) * 2012-09-07 2019-02-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Also Published As

Publication number Publication date
EP3134084A1 (en) 2017-03-01
EA035223B1 (ru) 2020-05-18
JP6696908B2 (ja) 2020-05-20
IL248408A0 (en) 2016-11-30
AR100191A1 (es) 2016-09-14
EA201692150A1 (ru) 2017-02-28
JP2017513908A (ja) 2017-06-01
CN106488768A (zh) 2017-03-08
PT3134084T (pt) 2021-05-11
IL248408B (en) 2022-06-01
NZ725576A (en) 2021-03-26
CA2946416C (en) 2022-07-19
BR112016024672A2 (pt) 2021-02-02
US20170042880A1 (en) 2017-02-16
EP3906921A1 (en) 2021-11-10
KR20160147934A (ko) 2016-12-23
DK3134084T3 (da) 2021-05-03
TWI724988B (zh) 2021-04-21
EP3134084B1 (en) 2021-03-17
CA2946416A1 (en) 2015-10-29
SG11201608657QA (en) 2016-11-29
UA121655C2 (uk) 2020-07-10
AU2015249232B2 (en) 2020-06-25
AU2015249232A1 (en) 2016-11-10
ES2874875T3 (es) 2021-11-05
JP2019189646A (ja) 2019-10-31
TW201622723A (zh) 2016-07-01
HUE054557T2 (hu) 2021-09-28
WO2015164869A1 (en) 2015-10-29
KR102474701B1 (ko) 2022-12-05
PL3134084T3 (pl) 2021-09-27

Similar Documents

Publication Publication Date Title
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
NZ763326A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
NZ724691A (en) Quinoline derivatives as smo inhibitors
PH12017502086A1 (en) Cancer treatments
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
NZ725595A (en) Compounds for treating brain cancer
EA201391114A1 (ru) Способы использования alk-ингибиторов
EP3280415A4 (en) Treatment of lung cancer with inhibitors of glutaminase
IL280158A (en) Methods of treating cancer with the PI3K inhibitor, GDC-0077
PH12017501879A1 (en) Methods for treating cancer
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
WO2015112705A3 (en) Therapeutic combinations for treating cancer
MX2016004967A (es) Tratamiento para cancer pancreatico.
EA201692332A1 (ru) Борсодержащие ингибиторы протеасом для применения после первичной противораковой терапии
MY179141A (en) Dipicolylamine derivatives and their pharmaceutical uses
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида
MX2015010854A (es) Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
GB2546703A (en) Compounds

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration